164 related articles for article (PubMed ID: 37980166)
1. Comprehensive analysis of ZNF692 as a potential biomarker associated with immune infiltration in a pan cancer analysis and validation in hepatocellular carcinoma.
Cai H; Chen S; Wu Z; Wang F; Tang S; Li D; Wang D; Guo W
Aging (Albany NY); 2023 Nov; 15(22):13041-13058. PubMed ID: 37980166
[TBL] [Abstract][Full Text] [Related]
2. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
4. Identifies microtubule-binding protein
Wang W; Zhang J; Wang Y; Xu Y; Zhang S
Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
[TBL] [Abstract][Full Text] [Related]
5. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
Wang Y; Gong H; Cao Y
Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
[TBL] [Abstract][Full Text] [Related]
6. Pan-cancer analysis identifies RNA helicase DDX1 as a prognostic marker.
Gao B; Li X; Li S; Wang S; Wu J; Li J
Phenomics; 2022 Feb; 2(1):33-49. PubMed ID: 36939765
[TBL] [Abstract][Full Text] [Related]
7. ESCO2's oncogenic role in human tumors: a pan-cancer analysis and experimental validation.
Huang Y; Chen D; Bai Y; Zhang Y; Zheng Z; Fu Q; Yi B; Jiang Y; Zhang Z; Zhu J
BMC Cancer; 2024 Apr; 24(1):452. PubMed ID: 38605349
[TBL] [Abstract][Full Text] [Related]
8. Prognostic, Immunological, and Mutational Analysis of MTA2 in Pan-Cancer and Drug Screening for Hepatocellular Carcinoma.
Huang X; Tan J; Chen M; Zheng W; Zou S; Ye X; Li Y; Wu M
Biomolecules; 2023 May; 13(6):. PubMed ID: 37371463
[TBL] [Abstract][Full Text] [Related]
9. The importance of BUD13 in the prognosis of hepatocellular carcinoma revealed by pan-cancer analysis.
He H; Qiu Z
Cell Mol Biol (Noisy-le-grand); 2023 Jun; 69(6):41-48. PubMed ID: 37605593
[TBL] [Abstract][Full Text] [Related]
10. Pan-cancer analysis from multi-omics data reveals AAMP as an unfavourable prognostic marker.
Wang Y; Liu T; Zhang K; Huang RH; Jiang L
Eur J Med Res; 2023 Jul; 28(1):258. PubMed ID: 37501187
[TBL] [Abstract][Full Text] [Related]
11. Comprehensively prognostic and immunological analysis of VRK Serine/Threonine Kinase 1 in pan-cancer and identification in hepatocellular carcinoma.
Chen D; Zhou W; Chen J; Wang J
Aging (Albany NY); 2023 Dec; 15(24):15504-15524. PubMed ID: 38157278
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis.
Zhang XD; Liu ZY; Luo K; Wang XK; Wang MS; Huang S; Li RF
Sci Rep; 2023 Oct; 13(1):16859. PubMed ID: 37803063
[TBL] [Abstract][Full Text] [Related]
13.
Ke P; Bao X; Liu C; Zhou B; Huo M; Chen Y; Wang X; Wu D; Ma X; Liu D; Chen S
Transl Cancer Res; 2022 Oct; 11(10):3491-3505. PubMed ID: 36388050
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of the tumor-promoting effect and immune infiltration correlation MAZ from pan-cancer to hepatocellular carcinoma.
Wang M; Yang X; Meng Y; Jin Z; Cao J; Xiong L; Xiong Z
Int Immunopharmacol; 2023 Feb; 115():109660. PubMed ID: 36623412
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer analysis of the oncogenic effects of G-protein-coupled receptor kinase-interacting protein-1 and validation on liver hepatocellular carcinoma.
Wang T; Su K; Wang L; Shi Y; Niu Y; Zhou Y; Wang A; Wu T
Adv Clin Exp Med; 2023 Oct; 32(10):1139-1147. PubMed ID: 36994687
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.
Bai KH; Zhang YY; Li XP; Tian XP; Pan MM; Wang DW; Dai YJ
Comput Struct Biotechnol J; 2022; 20():5226-5234. PubMed ID: 36187930
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of TLX2 in pan cancer as a prognostic and immunologic biomarker and validation in ovarian cancer.
Chen B; Ding X; Wan A; Qi X; Lin X; Wang H; Mu W; Wang G; Zheng J
Sci Rep; 2023 Sep; 13(1):16244. PubMed ID: 37758722
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis suggests histocompatibility minor 13 is an unfavorable prognostic biomarker promoting cell proliferation, migration, and invasion in hepatocellular carcinoma.
Liu J; Li W; Wu L
Front Pharmacol; 2022; 13():950156. PubMed ID: 36046831
[TBL] [Abstract][Full Text] [Related]
19. Potential Diagnostic and Prognostic Values of CBX8 Expression in Liver Hepatocellular Carcinoma, Kidney Renal Clear Cell Carcinoma, and Ovarian Cancer: A Study Based on TCGA Data Mining.
Lin J; Chen L; Wu D; Lin J; Liu B; Guo C
Comput Math Methods Med; 2022; 2022():1372879. PubMed ID: 35813444
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma.
Liu C; Qu Z; Zhao H; Wang P; Zhan C; Zhang Y
BMC Bioinformatics; 2023 May; 24(1):192. PubMed ID: 37170221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
